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The tumour microenvironment (TME) forms a major obstacle in effective cancer treatment
and for clinical success of immunotherapy. Conventional co-cultures have shed light onto
multiple aspects of cancer immunobiology, but they are limited by the lack of physiological
complexity. We develop a human organotypic skin melanoma culture (OMC) that allows
real-time study of host-malignant cell interactions within a multicellular tissue architecture.
By co-culturing decellularized dermis with keratinocytes, fibroblasts and immune cells in the
presence of melanoma cells, we generate a reconstructed TME that closely resembles
tumour growth as observed in human lesions and supports cell survival and function. We
demonstrate that the OMC is suitable and outperforms conventional 2D co-cultures for the
study of TME-imprinting mechanisms. Within the OMC, we observe the tumour-driven
conversion of cDC2s into CD14+ DCs, characterized by an immunosuppressive phenotype.
The OMC provides a valuable approach to study how a TME affects the immune system.
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Targeting immunomodulatory pathways within the tumourmicroenvironment (TME) entered centre stage in cancertreatment1. Despite promising clinical results of novel
cancer immunotherapies, such as immune checkpoint blockade
to treat melanoma skin cancer, clinical efficacy is limited and only
a minority of patients displays long-lasting clinical responses. It is
widely accepted that, in particular, an immunosuppressive TME
represents a major hurdle to cancer clearance by immune cells2–4.
Human melanoma models that resemble the complex tissue
architecture can improve our understanding of the contribution
of the TME to its immunosuppressed state5. This will be pivotal
for the design of novel strategies that tackle immunosuppressive
networks in melanoma to overcome immunotherapy failure.
Over the past decades, a vast array of experimental approaches
has been devised to study the melanoma TME, each presenting
unique strengths and flaws6. Those models range from two-
dimensional (2D) cultures to whole tissue explants. Albeit
informative for basic aspects of cancer biology, 2D culture sys-
tems are a poor copy of the in vivo cellular environment, as they
do not accurately mimic the meshwork of human tissues. Cells in
tissue face complex and structurally heterogeneous three-
dimensional (3D) architectures, and are exposed to a multitude
of cellular and extracellular parameters. Each of those factors can
influence tumour growth and the ability of stromal and immune
cells to orchestrate immune responses locally5,7. Tissue explants
obtained from a patient’s tumour can be cultured ex vivo for
microscopic evaluation, or implanted into immunodeficient mice.
Tissue explants and patient-derived xenografts (PDXs) retain
cell–cell interactions as well as some tissue architecture of the
original tumour and are very useful to monitor natural growth of
cancer and to investigate tumour heterogeneity8. Nevertheless,
PDXs lack a functional immune component, limiting their
applicability for the study of therapeutic responses to immu-
notherapy9. On the other hand, tumour explants can only assess
pre-existing tumour immune infiltration (as found at the time of
tissue resection), and as such only provide a snapshot. In con-
clusion, the human melanoma microenvironment including its
immune cell components is difficult to mimic using current
experimental models.
The potential of a human culture system that accurately
mimics the in vivo milieu, while having the benefit of a
laboratory-controlled environment, has inspired researchers to
develop 3D models of skin in which skin cancers, such as mel-
anoma, can be propagated (also referred to as skin equivalents or
organotypic cultures). In these models, human epidermal cells
and melanoma cell lines, with different invasive capacities, are
seeded onto fibroblasts-enriched, animal-derived collagen matri-
ces10–12. Others developed organotypic cultures based on acel-
lular, de-epidermized human dermis or self-assembled living
sheets made with human fibroblasts secreting their own extra-
cellular matrix (ECM), to obtain a model that more closely
resembles the multifaceted skin tissue13–16. However, despite
important contributions to the field, organotypic skin cultures of
melanoma that encompass both stromal- and immunocompe-
tence have never been described.
Within the TME, antigen-presenting dendritic cells (DCs) play
an important role in stimulating tumour-specific cytotoxic T cells,
thus driving immune responses against cancer17,18. Consensus
nomenclature for immune myeloid cells classifies human DCs as
conventional DCs (cDCs) and plasmacytoid DC (pDC). cDCs can
be further subdivided into cDC1 (CD141+ DCs) and cDC2
(CD1c+ DCs) subsets19. Despite their crucial role in anti-cancer
immunity, evidence suggests that DCs in tumours become largely
defective and are no longer capable to alert the immune system to
cancer. Furthermore, they are often outnumbered by other
myeloid cell subsets, such as tumour-associated macrophages
(TAMs) and myeloid-derived suppressor cells (MDSCs) that
actively suppress the immune system20–22. Moreover, we and
others have recently described the enrichment of a myeloid cell
population in the circulation of advanced stage cancer patients
that co-expresses markers of monocytes/TAMs (such as CD14,
CD163) and cDC2s (CD1c)23–25. Given their phenotypic dis-
tinction from monocytes and macrophages, these cells are called
‘CD14+ DCs’24. CD14+ DCs infiltrate both primary and meta-
static tumour sites, and may attenuate the efficacy of anti-cancer
immunotherapies23. How these CD14+ DCs are generated
remains yet to be determined.
Building on previous knowledge16, in this study we develop a
human organotypic skin melanoma culture (hereafter referred to
as OMC), which contains both stromal and immune components.
We validate our OMC by exploring functional plasticity of
naturally circulating cDC2s that infiltrate the reconstructed
melanoma tissue. Interestingly, we observe that the presence of a
tumour within the engineered TME leads to the transformation of
normal immunostimulatory cDC2s into CD14+ DCs, with a
phenotype matching their in vivo counterpart and an impaired
ability to stimulate T-cell proliferation. Our results highlight how
the generated OMC is instrumental to study tumour-induced
events within the TME, that could otherwise not be addressed by
the static assessment of tissue biopsies.
Results
Human OMC mimics natural primary human melanoma
lesions. A decellularized dermis was used as a scaffold to generate
OMCs (Fig. 1a). Histochemical evaluation of dermal markers
demonstrated that physical decellularization (outlined in the
method section) of the human dermal scaffold did not disrupt its
complex extracellular matrix architecture (elastin and collagen
fibres), and preserved an intact basement membrane (BM), cru-
cial for adhesion of keratinocytes (KCs) and development of an
epidermal layer (Supplementary Fig. 1a, b). Quantitative assess-
ments of the decellularized dermis confirmed the lack of cellular
(nuclei) and vascular (CD31) components (Supplementary
Fig. 1c–f).
To generate the OMC, primary human fibroblasts (Fbs), KCs
and melanoma cells are incorporated onto a decellularized, de-
epidermized dermis, and kept under specific culture conditions
until a fully differentiated epidermal layer with interspersed
tumour clusters is formed (Fig. 1a). To mimic melanoma growth
in the OMC, we co-seeded KCs with melanoma cells on the basal
membrane layer, at different KC-to-tumour cell ratios. Histolo-
gical analysis of model tissue sections and comparison to primary
human tumour biopsies showed that the KC-to-tumour cell ratio
is critical. At low KC-to-tumour cell ratios, extensive proliferation
of melanoma cells negatively affects the morphology of the
epidermal layer. Co-seeding large amounts of fast-dividing
tumour cells with epidermal cells, caused the tumour cells to
outnumber KCs, thereby affecting KC differentiation and
preventing the formation of a fully differentiated epidermis
(Supplementary Fig. 2). The optimal cell seeding concentration,
defined as the amount of KCs and melanoma cells that preserves
epidermal differentiation and morphology, while allowing the
formation of compact nests of tumour cells that infiltrate the
underneath dermis, was found to be 25 KCs:1 melanoma cell
(Fig. 1b, Supplementary Fig. 2). The proliferation of melanoma
cells was determined by a triple Ki67/tumour marker/DAPI
staining on OMC sections and Ki67 intracellular staining on the
digested OMC suspensions (Fig.1b).
Multiplex fluorescence immunohistochemistry, using two
different Fb-associated markers (FSP1 and FAP), along with the
tumour marker, showed melanoma cells and Fbs interacting
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Fig. 1 Human OMC generation and characterization. a Overview of the OMC generation (prior to immune cell addition). b Histological comparison of
tissue sections obtained from primary tumour lesion (left) and OMC (right), showing epidermal and dermal compartments with interspersed tumour cells.
Haematoxylin-eosin staining, representative pictures (n= 3). Representative areas (n= 3) of primary tumour lesion (left) and OMC (right), showing triplex
fluorescent staining of Ki67 (magenta), tumour marker (yellow) and DAPI (blue) fluorescence IHC staining. Composite and single colour images of higher
magnification are shown. Arrows indicate proliferating tumour cells. Representative flow cytometry histogram of Ki67+ cells measured within the OMC-
digested live CD45-negative fraction. c Multiplex fluorescence IHC shows representative area (n= 3) of the tumour lesion (left) and the OMC (right)
containing fibroblasts (fibroblast-specific protein 1, FSP1+ cells, magenta) and melanoma cells (tumour marker (tyrosinase and SOX10)+ cells, yellow).
DAPI (blue) indicates nuclei. Inserts show higher magnification. Pseudo-DAB of isolated fluorescent channels of the same areas are shown and fibroblasts
are indicated with arrows. Scale bars, 100 μm. Source data are provided as a Source data file.
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within the OMC (Fig. 1c, Supplementary Fig. 3). Taken together,
these observations show that the OMC mimics the invasive
growth of tumour cells into the dermis, closely resembling
malignancy-associated lesions in human skin.
The OMC microenvironment facilitates cell–cell interactions.
A major objective to exploit OMCs is to study human
host–tumour interactions. In this study, we incorporated a major
subset of DCs directly isolated from the peripheral blood (cDC2s,
phenotypically defined as CD1c+CD14−)23,24, into the dermal
compartment of a fully differentiated OMC (day 19, Fig. 2a,
Supplementary Movie 1).
After immunohistochemical staining, the distribution of cDC2s
was assessed by reconstructing ×20 images into overviews of
entire tissue sections (Fig. 2b–d, Supplementary Fig. 4). As a
simple metric to quantify the cell density and location within the
tissue area (or region of interest, ‘ROI’; Supplementary Fig. 4b),
we computed the amount of immune cells and other cells
(including stromal and epidermal cells), based on cell segmenta-
tion and phenotyping using inForm (Fig. 2b, top panel).
Enumeration of viable, single cDC2s was obtained with
qualitative assessment of signal intensities, analogous to flow
cytometry data, for cytometric image analysis as shown in Fig. 2b
(bottom panel), followed by microscopic evaluation. Live cells
were defined as Cl. Cas 3−, based on Cleaved-Caspase-3 staining,
single immune (CD45+ DAPI+) events (Fig. 2c). We found that
cDC2s were homogeneously distributed throughout the recon-
structed melanoma tissue (±20 cDC2s counted per mm2)
(Fig. 2d). Altogether, these findings demonstrate that the OMC
is a potentially valuable tool to study immune cells within
the TME.
DCs interact with melanoma cells in a human OMC environ-
ment. Immunohistochemistry end point analysis of fixed OMCs
revealed that cDC2s in the dermal compartment were in close
proximity with both melanoma cells and Fbs (Fig. 3a). To con-
firm that cDC2s actively interact with cells in their surrounding
niche and engage in cell-to-cell interactions with tumour cells, we
exploited live two-photon microscopy with a time-lapse setting
(Fig. 3b–f, Supplementary Fig. 5). Combination of fluorescent
signal (live-cell visualization) with second harmonic generation
(SHG, elicited by collagen fibre bundles) delivers information on
the 3D anatomy of OMCs. Like in natural skin, collagen fibres
were organized in heterogeneous networks, including randomly
arranged loose collagen fibres and aligned in more compacted
collagen bundles (Fig. 3b, Supplementary Fig. 1a, Supplementary
Fig. 5a, d). cDC2s were highly dynamic, as evidenced by a typical
hand-mirror shape (Fig. 3c, Supplementary Fig. 5b, c), char-
acteristic of amoeboid motility. cDC2s displayed a leading edge,
consisting of multiple dendrites that intercalated between tissue
structures, followed by the cell body containing the nucleus, and a
posterior tail (uropod). Analysis of DC shape and degree of cell
protrusion did not reveal significant differences with respect to
their distance from a tumour (Supplementary Fig. 5a–c). Fur-
thermore, we observed that GFP-expressing melanoma BLM cells
(BLM-GFP) showed intense membrane dynamics, evidenced by
protrusive and retractile activity (Fig. 3d). Interestingly, cDC2s in
our OMC actively interacted with live tumour cells and even
sampled tumour-derived cellular microparticles (or blebs),
released by the BLM-GFP cells into the ECM (Fig. 3e, f, Sup-
plementary Movie 2,3 and Supplementary Fig. 5d–f). Dynamic
DC-tumour cell interactions were observed as early as a few hours
after immune cell injection, over periods of at least 30 min
(Fig. 3e, Supplementary Fig. 5f). Tumour blebs remained intact as
evidenced by the retained cytoplasmic GFP. Taken together, these
observations clearly indicate that the OMC represents a promis-
ing and valuable platform for accurate investigation of cellular
interplay and function, in an in vivo-like skin tissue architecture.
cDC2s convert into CD14+ DCs in human OMCs. We and
others have previously described the enrichment of CD14+ DCs
in metastatic melanoma, leukaemia and breast cancer
patients23,24,26. Giving their clinical relevance in different tumour
types, we next evaluated whether direct tumour influence in the
OMC could convert immunocompetent cDC2s into CD14+ DCs.
Nowadays, cDC2 directly isolated from peripheral blood are used
to prepare DC vaccines to treat cancer patients27,28. Moreover,
given their relevance in driving anti-tumour T-cell responses, also
in the context of checkpoint inhibitor therapy29, it would be
important to know if these immunostimulatory cells have the
potential to become immunosuppressive within the TME.
To test this, we studied how the TME of three different
melanoma cell lines (BLM, Mel624, A375) modulated the
phenotype and function of immunocompetent cDC2s. Tumour-
free organotypic skin cultures (OSCs) were generated as controls.
We obtained highly purified cDC2s from healthy donors (purity
>96%. Supplementary Fig. 6a), including an additional step of
CD14+ cell depletion, and injected them into OSCs or OMCs.
After 2 days of culture, organotypic cultures were enzymatically
and mechanically digested. Supplementary Fig. 6b shows the
gating strategy applied for the discrimination of live immune
CD45+ and non-immune CD45− cells in the digested OSCs
and OMCs.
Interestingly, we observed induction of the CD14 monocytic
marker on cDC2s isolated from OMCs, compared with cells
harvested from OSCs (Fig. 4a). Figure 4a shows representative
contour plots identifying two distinct populations: cDC2s (CD1c+
CD14− cells, orange) as originally injected, and cells converted
into CD14+ DCs (CD1c+CD14+ cells, green). Pie charts in Fig. 4b
illustrate how, in the presence of melanoma, frequencies (mean ±
SD) of cDC2s and CD14+ DCs change, towards an accumulation
of the latter and a concomitant prominent reduction of cDC2s in
the TME, compared with OSCs. This phenomenon was
consistently observed throughout all experiments and indepen-
dent of the melanoma cell line used (Fig. 4c). Time-course analysis
revealed that the accumulation of CD14+ DCs occurred already
upon overnight culture in the OMC, and further increased over
time (48 and 72 h after injection) (Supplementary Fig. 7a, b). To
better define these cells, we assessed whether differences in the
expression of the monocytic marker, CD14, reflected additional
changes characteristic for CD14+ DCs. We observed that these
cells displayed lower CD1c, CD86 and HLA-DR (GeoMFI CD14+
DCs/cDC2s ratio <1.0) and also expressed higher levels of PD-L1
(GeoMFI CD14+ DCs/cDC2s ratio >1.0) (Fig. 4d). Interestingly,
besides CD14 upregulation, we found that CD14+ DCs expressed
higher levels of markers typically associated to TAMs: CD163,
CD206 and MerTK (GeoMFI CD14+ DCs/cDC2s ratio >1.0)
(Fig. 4e). Of note, changes in PD-L1 and CD163 expression were
not observed as early as 8 h, but became evident at longer
exposure time within the TME (Supplementary Fig. 7c).
To determine whether soluble factors might be responsible for
cDC2 conversion, we exposed cDC2 DCs to conditioned media
(CM) collected from BLM tumour cells and OMC, and observed
that both CM drove the conversion of freshly isolated cDC2 into
CD14+ DCs (Fig. 5a), as opposed to control medium. We
therefore examined secretome profiles of tumour-conditioned
(BLM-CM and OMC-CM) and control media (Fb-CM and OSC-
CM) (Fig. 5b), and focused our attention on CCL-2, IL-6 and
PGE2, factors known to play a role in tumour modulation of
myeloid functions30–32. Particularly, while CCL-2 was found
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co-expressed amongst all CM tested (OMC-CM, BLM-CM, Fb-
CM and OSC-CM); IL-6 was mainly detected in OMC-CM and
BLM-CM. Moreover, we observed that PGE2 was selectively
expressed in OMC-CM, but completely absent in the other
conditions. This was in line with the observation that only rhIL-6
and rhPGE2, but not rhCCL-2, drove the conversion of
stimulatory cDC2s towards immunosuppressive CD14+ DCs
(Fig. 5c). The role of rhIL-6 in modulating the generation of
CD14+ DCs was confirmed by the significant reduction induced
upon addition of the IL-6 blocking antibody (Fig. 5d). In addition,
IL-6 blockade also partially abrogated the immunosuppressive
modulation of cDC2 induced by either BLM-CM or OMC-CM.
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Fig. 2 The OMC microenvironment sustains immune cell survival and distribution. a Overview of the experimental approach used to obtain an
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In order to further investigate the importance of dimension-
ality in the tissue microenvironment, we performed intra-donor
comparisons (n= 4) of cDC2s, isolated from OMCs, to those co-
cultured with the same tumour cells in conventional 2D co-
cultures. Percentages of CD14+ DCs were significantly lower in
2D co-cultures compared to those isolated from OMCs
(Supplementary Fig. 8a, b), providing additional evidence for
the importance of 3D organotypic cultures that clearly mimic a
tissue microenvironment. Moreover, CD14+ DCs generated in
2D always failed to upregulate CD163 and MerTK, and had a
much lower expression of PD-L1 compared with cells cultured in
the OMC (Fig. 5e and Supplementary Fig. 8c). Altogether, these
data demonstrate that (1) within the OMC the presence of a
tumour drives cDC2s towards a different myeloid cell subset
phenotypically resembling CD14+ DCs, (2) the observed
phenomenon is tumour-dependent since OSCs lacking tumour
cells contain significantly less cells expressing CD14, (3) tumour-
induced secretion of IL-6 and PGE2 is at least in part responsible
for cDC2 DC conversion, (4) the cross-talk between melanoma
cells and fibroblasts, within the reconstructed OMC, causes
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Fig. 3 Visualization of cDC2-tumour cell interaction. a Section of OMC showing multiplex fluorescence immunohistochemistry representative area.
cDC2s (CD45+ cells, green) are found in close proximity to melanoma cells (tumour (tyrosinase and SOX10)+ cells, yellow) and fibroblasts (FAP+ cells,
magenta). DAPI (blue) indicates nuclei (n= 2). b PKH26 (yellow) and second harmonic generation (SHG, cyan) signals of multiphoton images, acquired
with excitation wavelength (λ) of 950 nm. PKH26 signal indicates cDC2s; SHG was generated by collagen bundles. c Characteristic amoeboid behaviour of
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950 nm]. BLM cells showed high cellular dynamics (dotted lines; protrusion, white arrowhead and retraction, blue arrow). e, f Representative time points
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increased secretion of PGE2, underlining the added value of a
multicellular microenvironment system and (5) 3D multicellular
skin cultures are essential, as conventional 2D co-cultures do not
recapitulate the complete CD14+ DC phenotype.
Tumour-induced CD14+ DCs display immunosuppressive
function. To functionally characterize tumour-induced CD14+
DCs, we next performed qRT-PCR on cDC2s and CD14+ DCs
FAC-sorted 18 h post-injection. We confirmed at the tran-
scriptomic level that CD14+ DCs from OMCs express CD14,
CD163 and CD206 genes (Supplementary Fig. 9a), consistent
with protein surface expression levels as measured by flow cyto-
metry (Fig. 4c, d). Interestingly, we observed that these CD14+
DCs generated within the OMC also expressed higher levels of
markers previously linked to human myeloid cells endowed with
suppressive activity: XBP1, THBS1, IL-6, PTGS2, and HIF1A
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(Fig. 6a, Supplementary Fig. 9b)30,33. At the protein expression
level, we confirmed that only CD14+ DCs promptly produced IL-
6 (11.1% vs 0.53%), upon TLR4 stimulation (Fig. 6b). Intrigu-
ingly, we observed that these cells could also be distinguished
based on their S100A9 expression (Fig. 6c), underlining another
similarity to already described regulatory myeloid cell features34.
Of note, the immunosuppressive molecule IDO1, often found in
association with tolerogenic DCs35 was predominantly expressed
in cDC2s that still retained a clear DC phenotype upon interac-
tion with tumour cells (Fig. 6a). This suggests that within OMCs,
injected cDC2s follow two different fates: (1) they become tol-
erogenic cDC2s; (2) they convert to CD14+ DCs. To further
investigate if these cDC2s also functionally reverted to immu-
nosuppressive myeloid cells, we performed mixed lymphocyte
reactions to test their immunostimulatory potential. cDC2s
that acquired CD14 during culture, were less capable of stimu-
lating allogeneic CD3+ T cells when compared with cDC2s that
lacked CD14 (Fig. 6d), and this stimulatory ability correlated with
their HLA-DR expression (Fig. 6e). Similarly, they were sig-
nificantly less able to induce autologous T-cell activation (Fig. 6f).
Of note, we observed that CD14+ DCs, isolated from OSCs, were
already less stimulatory than cDC2s, but the presence of the
tumour further decreased their ability to stimulate T-cell pro-
liferation and activation (Supplementary Fig. 9c, d). Collectively,
our data show that cDC2s that acquire CD14 within OMCs,
represent a functional distinct myeloid population induced by
the TME.
CD14+ DCs in OMCs resemble those found in melanoma
lesions. Subsequently, we set out to compare CD14+ DCs
induced in the OMC with myeloid cells isolated from melanoma
lesions of stage IV metastatic melanoma patients. Using flow
cytometry analysis, we identified CD14+ DCs (green) and cDC2s
(orange) in melanoma lesions, similarly to what we previously
observed within OMCs (Fig. 7a). Pie charts in panel b summarize
the results obtained across three different patients. Further phe-
notypic analyses revealed the macrophage-like nature of these
ex vivo CD14+ DCs, characterized by a higher expression of
CD163, CD206 and MerTK (Fig. 7c). Histograms in panel c show
that ex vivo CD14+ DCs, identified within intra-tumoural CD45+
CD11c+ cells (Supplementary Fig. 10), have a phenotype that is
closer to that of CD14+ monocytes/macrophages (mono/macs,
red), rather than cDC2s. Moreover, we could confirm that also
ex vivo, CD14+ DCs expressed higher levels of PD-L1 when
compared to cDC2s. Overall, this ex vivo analysis of tumour
biopsies highlights the phenotypic similarity between CD14+
DCs reprogrammed within OMCs and those isolated from mel-
anoma lesions.
Patient-derived OMCs educate autologous monocytes. Finally,
we explored the suitability of the organotypic culture conditions
for different immune and non-immune cell subsets. In this
respect, we tested whether the dermal scaffold allows culture of
human lymphocytes, isolated from peripheral blood and meta-
static melanoma lesions. We observed that peripheral blood CD3+
CD4+ and CD3+CD8+ T cells could be recovered 2 days after
injection, with no loss or changes in the proportion of T-cell
subpopulations, compared with conventional 2D cultures (Sup-
plementary Fig. 11). Similarly, the frequencies of melanoma-
infiltrating lymphocytes, cultured for 2 days in a dermal scaffold
(Fig. 8a, b), were in line with the parallel ex vivo phenotypic
analysis of patient samples (Supplementary Fig. 12a). Further-
more, we used pairs of prospectively collected tumour material
and peripheral blood from melanoma patients (n= 3), for the de
novo generation of autologous patient-derived organotypic
models. In particular, CD45− cells (tumour and stromal popu-
lations) were injected in a dermal scaffold, and cultured for 48 h;
followed by injection of autologous blood circulating CD14+
monocytes (as a source of myeloid immune cells) and an addi-
tional 2day culture period. Analysis of patient-derived models
showed that HLA class I, Ki67 and expression of four tumour
antigens on melanoma cells was maintained, as compared with
the original tumour lesion (Fig. 8c, d and Supplementary Fig. 13).
A similar level of tumour-imprinting in infiltrating immune cells
was observed in this autologous setting, confirming and extending
the observations made in the melanoma cell line-derived OMCs.
Blood circulating CD14+ monocytes underwent the same phe-
notypic conversion as we observe for cDC2 DCs (HLA-DR
downregulation, and upregulation of CD14, MerTK and PD-L1)
when infiltrating the TME (Fig. 8d and Supplementary Fig. 12b).
Altogether, our results demonstrate that patient-derived organo-
typic models resembled melanoma lesions in terms of tumour-
specific characteristics, composition of tumour-infiltrating lym-
phoid cells, and the ability to induce changes in the phenotype of
myeloid cells.
Discussion
Three-dimensional, organotypic cultures of cancer types have the
advantage of recapitulating both histological and mutational
features of the original tumour, and can be propagated for
extended periods of time, thus facilitating experimenting36–38.
Yet, they fail to represent the multicellular composition of the
TME; in particular, the inclusion of stroma and tumour-
infiltrating lymphocytes has been only recently described39.
Among skin malignancies, melanoma is difficult to mimic due
to the structural complexity of the skin tissue. In the context
of human melanoma, local tumour growth was achieved in
in vitro skin equivalents, which, however, lacked an immune
Fig. 4 Identification and phenotypic characterization of CD14+ DCs isolated from the human OMC. a Two days after cDC2s injection, OMCs were
digested and cell suspensions were stained. Representative flow cytometry contour plots showing gated cDC2s (CD1c+CD14− cells) and CD14+ DCs
(CD1c+CD14+ cells) in OSCs (upper contour plots) and OMCs (lower counter plots). Results obtained with three different melanoma cell lines (BLM,
Mel624, A375) are shown. Numbers indicate the percentage of gated cells. b Pie charts depicting the frequency of cDC2s and CD14+ DCs in OSCs
and OMCs. Independent experiments were performed with three different melanoma cell lines: BLM (n= 8), Mel624 (n= 2), A375 (n= 2). Frequencies
from control OSCs are pooled (n= 12). Data are mean ± SD. c Graphs showing the frequency of cDC2s (p= 0.0005) and CD14+ DCs (p= 0.0005)
in OSCs and OMCs (across the three melanoma cell lines). A non-parametric two-tailed Wilcoxon signed-rank test was used for statistical analysis.
d Representative overlaid histogram plots showing expression of the indicated markers in cDC2s and CD14+ DCs isolated from OMCs. For each marker a
summary graph reporting the ratio of the geometric mean of the fluorescence intensity (GeoMFI) between CD14+ DCs and cDC2s isolated from OSCs and
OMCs is shown. A blue background indicates a GeoMFI ratio <1, higher expression in cDC2s; whereas a red background indicates a GeoMFI ratio >1, higher
expression in CD14+ DCs. At least n= 3 donors for each marker are included. The p values were estimated using a non-parametric two-tailed Wilcoxon
signed-rank test. e Representative histogram plots and GeoMFI graphs of macrophage-related markers CD163, CD206 and MerTK in cDC2s and CD14+
DCs isolated from OMCs. At least n= 3 donors for each marker are provided. The p values were estimated using a non-parametric two-tailed Wilcoxon
signed-rank test. Statistical significance was annotated as follows: *p < 0.05, ***p < 0.001. Source data are provided as a Source data file.
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compartment16. With the aim of filling this gap, we generated a
human multicellular skin microenvironment, amenable to con-
trolled experimental manipulation, suitable to explore cancer-
driven immune cell modulation within a complex tissue archi-
tecture. Similar to organotypic tumour cultures, the OMC we
developed, reproduces the spatial distribution of cells that
naturally constitute the skin. We observed that an optimal KC-to-
tumour cell ratio is essential to ensure the formation of the epi-
dermal layer, while allowing proliferation of tumour cells into
nests that infiltrate the underneath dermis. The decellularized
human tissue employed here provides natural skin stiffness and
tissue architecture of collagen and elastin fibres, advancing the
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study of tumour and immune cell migration and interaction.
Remarkably, the changes we observed on myeloid cell subsets,
including those isolated from melanoma patients, cultured in
OMCs (either allogeneic or autologous) did not require the
addition of exogenous growth factors or cytokines. Thus, con-
firming the suitability of the human decellularized dermal scaffold
to maintain tumour and immune representativeness of the ori-
ginal lesion. Further functional experiments would demonstrate
the employability of the scaffold for advanced T-cell experi-
menting. Potentially, the decellularized human tissue may
represent a better alternative to animal-derived scaffolds that may
act as a source of foreign antigen40.
The intra-tumoural infiltration and activation of myeloid cells,
such as DCs, has clinical relevance across different tumour
types18. Thus, understanding the mechanisms that regulate the
fate of individual DC subsets within the TME will be pivotal to
define strategies that revert DC immunosuppression while
simultaneously enhancing their activation41. In this regard, the
behaviour of antigen-presenting cells in organotypic tumour
cultures has never been addressed. We therefore validated the
OMC by following the response of circulating human cDC2s
within the reconstructed TME. cDC2s are phenotypically defined
as CD1c+CD14− and characterized by the ability to stimulate
cytotoxic T-cell responses, exemplified by their use in DC vac-
cination protocols27. We documented the interaction of cDC2s
with stromal and melanoma cells within the OMC, and attested
the local conversion of cDC2s into a distinct myeloid cell popu-
lation. Of note, this tumour-induced myeloid subset, character-
ized by the decreased expression of the DC marker CD1c and the
concomitant acquisition of monocyte/TAM markers (CD14,
CD163, CD206 and MerTK), is consistent with CD14+ DCs
already described in literature in the context of cancer-related
inflammation24,25. These findings argue in favour of the ability of
the OMC to recapitulate in vivo-like phenomena. While the
current literature indicates that CD14+ DCs may arise from
monocytes19, we here provide evidence for a new route of
melanoma-mediated conversion of cDC2s into CD14+ DCs. Such
cDC2s-inherent phenotypic plasticity is not counterintuitive, if
we reason that single-cell-RNA sequencing recently revealed the
unappreciated heterogeneity of blood cDC2s, isolated from
healthy individuals. Indeed, a cell cluster characterized by a
unique inflammatory gene signature, close to that of CD14+
monocytes, has been identified within the CD14-negative
cDC2 subset42. Functionally, the melanoma-induced CD14+
DCs described here, express genes (such as SSP1, PTGS2, IL-6)
previously associated with immunosuppressive myeloid cells30,33
and, like monocytes and macrophages, have poor T-cell stimu-
latory ability. The evolution of conventional DCs into regulatory
macrophage-like cells has been only proposed in murine
models43,44; in this study we report the ability of human, natu-
rally-occurring, mature cDC2s to be reprogrammed into CD14+
DCs. Indeed, human in vitro studies investigating this
phenomenon were performed using monocyte-derived DCs
(moDCs), which represent a poor surrogate of in vivo DCs45,46.
IL-6 and PGE2 were identified as factors involved in the
cDC2-to-CD14+ DC conversion. This is in line with their ability
to orchestrate immune myeloid modulation towards immuno-
suppression30–32. Interestingly, the PGE2 selective expression in
OMC-CM likely results from the cross-talk between melanoma
cells and fibroblasts within the reconstructed TME. This finding
supports the hypothesis that the multicellular dimensionality of
the TME plays a critical role in shaping cell phenotypes5,7. We
here showed that the phenotype of tumour-induced CD14+ DCs
was not obtained in parallel intra-donor 2D co-culture experi-
ments. In particular, although some expression of CD14 was
observed, these cells failed to express the TAM markers, CD163
and MerTK. The in vitro differentiation of myeloid cells to
acquire TAM traits usually requires ≥3 days47,48. However, we
believe that this rapid cDC2s conversion (within 3 days) could be
explained by the fact that tumour and immune cells are not
added in culture simultaneously, as usually performed in classical
2D co-culture experiments, but instead immune cells are exposed
to an already tumour-conditioned skin microenvironment. This
certainly leads to a stronger tumour-mediated effect and more
closely resembles the natural cDC2s entry into tumour tissues
in vivo. Intriguingly, CD14+ DCs developed within the orga-
notypic melanoma cultures shared important phenotypic simi-
larities with CD14+ DCs infiltrating human melanoma lesions.
Moreover, they express higher levels of TAM-related markers
(CD206, MerTK and CD163), compared to blood circulating
CD14+ DCs, we previously linked to lower immunological
response to DC-based vaccines in melanoma patients23,26. These
results demonstrate the added value of the OMC over classical
2D co-culture cell systems. Importantly, as highlighted by the
time-course analysis, the cDC2 conversion occurring in the
OMC at 48 h was even more profound after 72 h, indicating how
critical the immunomodulatory effect of the TME is on the
phenotype of myeloid cells. Our data indicate that the decel-
lularized human-derived dermis repopulated with stromal cells,
not only provides the correct extracellular space and guidance for
cells to engage in dynamic cell–cell and cell–matrix interactions,
but also offers the mechanical tissue stiffness as observed in vivo,
and which likely contributes to TAM differentiation49. Ex vivo
tumour-infiltrating CD14+ DCs are characterized by the
expression of the T-cell inhibitory molecule PD-L1. Interestingly,
the upregulation of this key immune escape molecule was higher
in tumour-educated myeloid cells within the OMC, and pro-
gressively increased over time, compared with those developed in
classical monolayer co-cultures. To this end, it would be of
interest to use the model to assess the modulation of immune
checkpoint inhibition.
Together, our results show that the OMC culture system offers
a number of advantages over two-dimensional culture systems. It
facilitates studying development of tumours in more complex 3D
Fig. 5 Effect of soluble factors and dimensionality on the CD14+ DC conversion and phenotype. a Frequency of CD14+ DCs upon culture of cDC2s in DC
medium (n= 5), BLM-conditioned medium (n= 5) or OMC-conditioned medium (n= 4). Each symbol represents an individual donor (Mean±SEM; one-
way ANOVA and Tukey’s multiple comparisons tests). b Heatmap of the indicated soluble factors in conditioned media (CM) from 2D-cultured Fibroblasts
and BLM cells, as well as from 3D-cultured OSC and OMC, as assessed by Luminex-based bead immunoassay and dedicated PGE2 ELISA. c Frequency of
CD14+ DCs in cDC2s cultured in DC medium (n= 4) only, in the absence or presence of recombinant human (rh) factors (n= 4). Each symbol represents
an individual donor (mean ± SEM; two-way ANOVA and Tukey’s multiple comparisons tests). d Fold change of the percentage of CD14+DCs relative to
their frequency in DC medium. IL-6 blockade attenuates the cDC2s conversion induced by rhIL-6 (n= 4), BLM-c.m. (n= 5) and OMC-c.m (n= 2). Each
symbol represents an individual donor (mean ± SEM; two-tailed paired t tests) (p= 0.0024). e Flow cytometry analysis shows phenotype of cDC2s and
CD14+ DCs isolated from OMCs and conventional tumour-cDC2 co-cultures (2D). Overlaid histograms for the indicated markers, from one representative
experiment out of four, are shown. Colour legends indicate: cDC2s (orange), CD14+DCs (green). Statistical significance was annotated as follows: *p <
0.05, **p < 0.01, ***p < 0.001. Source data are provided as a Source data file.
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tissues, such as skin, and at the same time investigating the effect
of interactions with components of the immune system, such as
DCs. These standardized OMC cultures can be used to get more
detailed insights in how tumours can suppress the immune
system.
We are well aware that, like most organotypic culture systems,
our OMC is limited by the absence of blood vessels and lym-
phatics, and thus events such as angiogenesis and leuko-
cyte extravasation cannot be mimicked. In order to overcome this
caveat, attempts have been made to engineer collagen matrices
containing a microvasculature network of endothelial cells, or to
integrate microfluidics with tissue engineering to mimic the
function of native microvessels50,51. Those approaches are still in
their early infancy and further development is needed52,53.
Within the OMC, DCs engage in dynamic interactions with
tumour cells that are distributed in the reconstructed TME. It
would be interesting to define the migratory nature of DCs
towards tumour cells, whether this is a stochastic process or
rather driven by a chemotactic gradient, secreted by the tumour.
To support this kind of analyses, the OMC culture as described
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Fig. 6 Functional characterization of cDC2s and CD14+ DCs isolated from human OMC. a Two days after total cDC2s injection, BLM-OMCs were
digested and CD1c+CD14− (cDC2s) and CD1c+CD14+ (CD14+DCs) subsets FAC-sorted for RNA extraction and molecular characterization by qRT-PCR.
Gene expression levels (2−ΔCt) for the indicated genes in cDC2s and CD14+DCs. Reported values for each gene are the means of n= 3 biological
replicates (mean ± SEM; two-way ANOVA and Sidak’s multiple comparisons test). ACTB was used as internal reference. Colour legends indicate: cDC2s
(orange), CD14+DCs (green). b IL-6 production assayed by intracellular cytokine staining in BLM-educated cDC2s, upon stimulation with LPS (1 μg/mL)
for 6 h. cDC2s and CD14+DCs were identified and gated based on CD1c and CD14 expression in CD45+ live single cells. Representative dot plots are
shown. Numbers indicate the percentage of gated cells. c Intracellular protein expression of S100A9 in tumour-educated cDC2s and CD14+DCs.
Representative GeoMFI histograms for BLM and Mel624 are shown. d Proliferation of allogeneic CD3+ T cells 5 days after co-culture with FAC-sorted
cDC2s and CD14+DCs. Scattered dot plots (five independent experiments, in triplicate (Exps. 1–2-3) and duplicate (Exps. 4-5) samples; mean ± SEM; one-
way analysis of variance (ANOVA) and Tukey’s multiple comparisons tests). Representative CFSE histogram plots from Exp. 2 are shown; numbers
indicate the percentage of gated cells. e Biplot of HLA-DR expression and induced allogeneic T-cell proliferation in Exps. 4 and 5. Correlation assessed by
linear regression. f Autologous T cells were co-cultured with cDC2s and CD14+DCs for 5 days and then stained for HLA-DR, CD25, CD3, CD8 and live/
dead marker. Percentage of activated CD25+HLA-DR+ cells in total CD3+ T cells is reported. Scattered dot plots (two independent experiments, in
triplicate samples (mean ± SEM; one-way analysis of variance (ANOVA) and Tukey’s multiple comparisons tests). Representative dot plots from Exp. 1 are
shown. Statistical significance was annotated as follows: **p < 0.01, ***p < 0.001, ****p < 0.0001. Source data are provided as a Source data file.
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here would require further optimization. In particular, to ensure
that location of both tumour cells (source of the chemotactic
gradient) and DCs (responders) is better controlled. For example,
by precise injection of the tumour and immune cells on opposite
sides of the OMC.
In the present study we describe the generation, characteriza-
tion and application of a human OMC, encompassing both
stromal and immune compartments. Importantly, in contrast to
patient-derived organotypic tumour cultures, our system does not
aim to assess pre-existing immune infiltration54, but rather has to
be viewed as a fully tuneable melanoma environment for the in-
depth investigation of early events that regulate tumour-
immunological mechanisms. Overall, we believe that the pro-
posed OMC will contribute to the identification of candidate
genes and molecules that contribute to immune escape
processes. Ultimately, this might even lead to the design of
novel therapeutic targeted approaches addressing the melanoma
microenvironment.
Methods
Cell culture, transduction, stable cell line development. Human melanoma cells
(BLM, BLM-GFP, Mel624 and A375) were tested to be mycoplasma-free,
authenticated by ATCC and maintained in Dulbecco’s modified Eagle’s medium
(DMEM, Gibco), supplemented with 5% foetal calf serum and 5% CO2 humidified
air at 37 °C. The Lenti6/Block-iT-shScramble (GFP) vector was a kind gift of Prof.
Peter Friedl (RIMLS, The Netherlands). The sequence of this construct does not
match any known mammalian genes. BLM cells were infected with lentiviral vector
and (10 µg/ml) polybrene and incubated at 37 °C, 5% CO2, overnight. Then the
medium was refreshed and cells were analysed after 72 h of treatment. A stable cell
line was selected with 5 µg/ml blasticidin. Recombinant human factors IL-6 (Cell
Genix), PGE2 (Pfizer) and CCL-2 (R&D Systems) were used in conversion
experiments (all 20 ng/ml) in the presence or absence of anti-IL-6 (1 µg/ml,
Invivogen).
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Isolation of human blood immune cells. Peripheral blood mononuclear cells
(PBMCs) were isolated from buffy coats obtained from healthy volunteers (San-
quin) and purified via centrifugation over a Ficoll density gradient (Axis-Shield) in
SepMate tubes (Stemcell technologies). cDC2s (CD1c+) cells were purified with
magnetic cell sorting (MACS) from healthy donor PBMCs using the CD1c
(BDCA1) DC isolation kit (Miltenyi Biotec). To obtain a highly purified CD1c+
CD14− population, a pre-depletion step of monocytes using CD14-MACS
microbeads (Miltenyi Biotec) was included in the original manufacturer’s protocol.
DC purity was assessed by staining with primary directly labelled antibodies: anti-
CD1c, anti-CD14 and anti-CD20 Abs (Supplementary Table 1). Purity levels higher
than 96% were achieved, determined by flow cytometry (Supplementary Fig. 6a).
For live imaging experiments, cDC2s were pre-labelled with the membrane dye
PKH26 (Sigma-Aldrich) according to manufacturers’ protocols and resuspended in
X-VIVO-15 medium (Lonza), supplemented with 2% human serum (HS, Sanquin).
Autologous or allogeneic CD3+ T cells used in T-cell co-culture experiments were
isolated using the Pan T-cell isolation kit (Miltenyi Biotec) following the manu-
facturer’s instructions. Peripheral blood monocytes were isolated using CD14-
MACS Microbeads (Miltenyi Biotec) according manufacturer’s instructions.
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Isolation of cellular and extracellular matrix human skin components. Gen-
eration of de-epidermized, decellularized dermis and isolation of human primary
keratinocytes from human abdominal and breast skin, derived from donors who
underwent surgery for abdominal wall and breast correction55. Briefly, human skin
was incubated for 5–10 min in phosphate-buffered saline (PBS) at 56 °C to allow
separation of the epidermis from the dermis. A de-epidermized human dermis was
obtained by incubating the dermis for one month in PBS containing gentamicin
(0.5 mg/ml; Life Technologies, Inc.) and antibiotic/antimycotic (Life Technologies,
Inc.) at 37 °C. Continuous cycles of freezing and thawing ensured the depletion of
all living cells in the dermis. Punches were prepared from this de-epidermized
dermis using an 8-mm biopter, exposed to additional freezing/thawing cycles and
frozen for further use. Keratinocytes were isolated from the epidermal layer by
trypsin treatment for 16–20 h at 4 °C, and then cultured in the presence of irra-
diated (3295 cGy for 4.10 min) mouse fibroblasts 3T3 cells. 3T3 cells were seeded at
a concentration of 3 × 104 cells per cm2 in Greens medium, which consisted of two
parts Dulbecco’s modified Eagle’s medium (Life Technologies), one part of Ham’s
F12 medium (Life Technologies), 10% foetal bovine serum (Hyclone), L-glutamine
(4 mmol/L; Life Technologies, Inc.), penicillin/streptomycin (50 IU/ml; Life Tech-
nologies, Inc.), adenine (24.3 μg/ml; Calbiochem, San Diego, CA), insulin (5 μg/ml;
Sigma, St. Louis, MO), hydrocortisone (0.4 μg/ml; Merck, Darmstadt, Germany),
triiodothyronine (1.36 ng/ml, Sigma), cholera toxin (10−10 mol/L, Sigma). The next
day keratinocytes were added at a concentration of 5 × 104 cells per cm2.
Keratinocytes-3T3 cells co-cultures were maintained for 3 days in Greens medium.
Thereafter, medium was replaced by Greens medium containing epidermal growth
factor (EGF, 10 ng/ml; Sigma), cells were expanded until 90% confluence and
stored in the liquid nitrogen. Keratinocytes were used at passage one or two. Adult
human dermal fibroblasts were purchased by ATCC and maintained in Fibroblast
medium (3:1 DMEM: Ham’s F12 Nutrient Mixture, Gibco) supplemented with
10% FCS, and expanded until 80% confluence. Passages three to nine were used for
the experiments.
Generation of the human organotypic skin melanoma culture. To generate the
OMC, 8 mm punch biopsy of de-epidermized, decellularized dermis was placed
carefully basal membrane side down on a transwell insert in a 24-well plate (24-
wells ThinCert, Greiner Bio-One) and 0.25 × 106 fibroblasts were seeded onto the
reticular dermal side (opposite to papillary side and basal membrane) of a de-
epidermized dermis, via centrifugal force (day 1), in Fibroblast medium (3:1
DMEM: Ham’s F12 Nutrient Mixture, Gibco) supplemented with 10% FCS. The
plate was centrifuged for 1 h at ~300 × g. After centrifugation, the de-epidermized
dermis was maintained in Fibroblast medium for 2 days at 37 °C, to allow cellular
proliferation and distribution through the structural collagen bundles and elastin
fibres. After 2 days of culture, the repopulated de-epidermized dermis was turned
basal membrane side up in the transwell insert and keratinocytes were seeded
together with melanoma cells (BLM, Mel624 or A375) onto the papillary side of the
dermal scaffold (day 3). The OMC was cultured submerged for 3 days in PONEC
medium containing 5% serum (PONEC 5% medium), to allow proliferation of
keratinocytes and tumour cells (day 6). PONEC 5% medium consists of two parts
Dulbecco’s modified Eagle’s medium (Life Technologies, Inc.), one part of Ham’s
F12 medium (Life Technologies, Inc.), 5% calf serum (Hyclone), L-glutamine
(4 mmol/L; Life Technologies, Inc.), penicillin/streptomycin (50 IU/ml; Life
Technologies, Inc.), adenine (24.3 µg/ml; Calbiochem, San Diego, CA), insulin
(0.2 µmol/l; Sigma, St. Louis, MO), hydrocortisone (1 µmol/l; Merck, Darmstadt,
Germany), triiodothyronine (1.36 ng/ml, Sigma), cholera toxin (10−10 mol/L,
Sigma), ascorbic acid (50 µg/ml; Sigma). Thereafter, the OMC was shifted to the
air–liquid interface and cultured for 11 days in PONEC medium without serum,
supplemented with keratinocyte and epidermal growth factors (PONEC 0%
medium), during which a fully differentiated epidermal layer is formed (day 17).
PONEC 0% medium consists of two parts Dulbecco’s modified Eagle’s medium
(Life Technologies, Inc.), one part of Ham’s F12 medium (Life Technologies, Inc.),
L-glutamine (4 mmol/L; Life Technologies, Inc.), penicillin/streptomycin (50 IU/
ml; Life Technologies, Inc.), adenine (24.3 µg/ml; Calbiochem, San Diego, CA),
L-serine (1 mg/ml; Sigma), L-carnitine (2 µg/ml, sigma), bovine serum albumin
lipid mix (palmitic acid 25 µmol/l; arachidonic acid 7 µmol/l; linoleic acid 15 µmol/
l; vitamin E 0.4 µg/ml; all from Sigma), insulin (0.1 µmol/l; Sigma, St. Louis, MO),
hydrocortisone (1 µmol/l; Merck, Darmstadt, Germany), triiodothyronine
(1.36 ng/ml, Sigma), cholera toxin (10−10 mol/L, Sigma), ascorbic acid (50 µg/ml;
Sigma), keratinocyte growth factor (5 ng/ml, Sigma), epidermal growth factor
(2 ng/ml, Sigma). At this point, the OMC was conditioned for 2 days with X-
VIVO-15 medium (Lonza) supplemented with 10% human serum (Sanquin), to
sustain survival of immune cells in the reconstructed microenvironment (day 19).
Ex vivo culture of immune cells, which can be freshly isolated from peripheral
blood circulation or separated from the tissue they infiltrate, can be a critical
procedure due to the fragile nature of those cell types when dissected from their
original microenvironment. At day 19, 0.1–0.5 × 106 cDC2s were microinjected
into the dermis using a microneedle array system (NanoPass Technologies Ltd,
Israel). The microneedle array holder was connected to a manual syringe pump
(1 ml, BD). Microinjection was performed using air pressure (Supplementary
Movie 1). Care was taken not to allow the microneedles to rupture the regenerated
skin. Immunocompetent OMCs were cultured for an additional 2 days in X-VIVO-
15 medium plus 10% human serum. For experiments that assessed DC phenotype
and function, melanoma cells were incorporated (1) together with Fbs onto the
dermal scaffold (day 1), and (2) co-seeded with keratinocytes onto the basal
membrane (day 3). The double seeding procedure of melanoma cells was per-
formed to guarantee efficient melanoma conditioning of the reconstructed
microenvironment, in a way that would more closely recapitulate in vivo tumour-
associated tissues.
Patient material. Tumour specimens were collected from metastatic melanoma
patients who underwent a surgical resection with palliative intent. The following
cases were analysed: Patient 1, dermal and subcutaneous metastasis axilla; Patient
2, adrenal metastasis; Patient 3, liver metastasis; Patient 4, subcutaneous metastasis
and Patient 5, brain metastasis. The study protocol (CMO dossier-number 2016-
2758) was approved by our Institutional Review Board, Centrale Commissie
Mensgebonden Onderzoek (CCMO), and written informed consent was obtained
from all patients.
Tumour dissociation. Melanoma cell suspensions were obtained from tumour
samples by enzymatic and mechanic digestion using the gentleMACS Dissociator
(Miltenyi, Bergisch-Gladbach, Germany). Briefly, tumour specimens were minced
under sterile conditions into small pieces and digested over 1 h at 37 °C following
the gentleMACS Dissociator protocol (Miltenyi). The resulting cell suspension was
filtered through a 70-μm mesh (BD Biosciences, San Jose, CA, USA), the red blood
cells were lysed, and the cell suspension was washed with RPMI. Cells were stored
in liquid nitrogen until use. The same procedure was used for processing OMCs
and OSCs, for the isolation and analysis of immune cells.
Chromogenic IHC and manual digital cell density analysis. Slides of 4- or 6-µm
thickness were cut from formalin-fixed, paraffin-embedded (FFPE) primary mel-
anoma tissue blocks, OMCs and dermal scaffold before and after decellularization.
Haematoxylin-Eosin (HE) and Elastica van Gieson histological stainings were
performed according to standard protocols. For chromogenic immunohis-
tochemistry, antigen retrieval was performed by rehydrating and boiling the slides
in either Tris-EDTA buffer (pH 9; 643901; Klinipath) for 10 min or in pronase
(0.1% protease XIV, P5147-5G; Sigma) for 6 min at 37 °C. Protein blocking was
achieved using Normal Antibody Diluent (VWRKBD09-999; ImmunoLogic), fol-
lowed by wash in PBS on a rocking table at low speed. Primary antibodies (listed in
Supplementary Table 2) were incubated for 1 h at room temperature. Subsequently,
primary antibody detection and chromogenic visualization was performed with
BrightVision poly-HRP (DPVR110HRP; ImmunoLogic) for 30 min at room tem-
perature and DAB (VWRKBS04-999; ImmunoLogic) or NovaRed (SK-4800;
Vector) for 7 min at room temperature. After dehydration, slides were counter-
stained with haematoxylin for 1 min and enclosed with Quick-D mounting med-
ium (7281; Klinipath). A selection of 5 representative original brightfield images
per HE-stained section was loaded into the open source-imaging platform, Fiji
(ImageJ 64 Bit for Windows), and used for blinded histopathologic evaluation of
cell nuclei density, using the specific cell counter plug-in. Relative vascularity was
determined in three representative CD31-stained tissue sections, by CD31-based
Fig. 8 Analysis of patient-derived OMC. a, b Comparison of melanoma patient’s cell suspension cultured in a de-epidermized human dermis versus ex vivo
analysis. Two days after injection, microtissues containing the patient material were fixed and processed for paraffin embedding. a Multiplex IHC staining on
tissue sections was performed using the following antibodies: CD3 (red), CD8 (light blue) and tumour marker (white). The latter consists of a mix of antibodies
recognizing the melanoma antigens: HMB45 (gp100), MelanA (MART-1), Tyrosinase and SOX10. Representative H&E stain and multicolour composite pictures
for T-cell-related antibodies (T-cell panel) are shown (n= 1, Pt. 3). Scale bar, 50 µm. b Cytometric image manual quantification analysis of multiplex IHC
sections (n= 7) shown in panel (a), to identify lymphocytes (tumour marker-CD3+CD8+ and Tumour marker-CD3+CD8− events). Mean ± SEM; two-tailed
unpaired t tests) (p < 0.0001) (Gating strategy is shown in Supplementary Fig. 11). c, d Representative IHC images of tumour-specific characteristics in original
melanoma lesion (left) and pt-derived OMC (right) (n= 3). Scale bars, 100 μm. d Overview of tumour-specific characteristics in original melanoma lesions and
pt-derived OMCs. Ctrl is control melanoma tissue. e Graphs reporting the Geometric mean of fluorescence intensity (GeoMFI) of the indicated markers in CD14
+ monocytes cultured within OSCs or pt-derived OMCs (n= 3; except for PD-L1: n= 2). Source data are provided as a Source Data file.
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tissue segmentation using advanced Image Analysis software (inform 2.4.1;
PerkinElmer).
Fluorescent multiplex immunohistochemistry. Formalin-fixed, paraffin-
embedded (FFPE) OMCs were sectioned following a perpendicular orientation
with respect to the direction of the epidermal layer (Supplementary Fig. 4a). Tissue
sections (6-µm thickness) cut at a distance of ~200 µm were stained for fluorescent
multiplex IHC. Immunofluorescent visualization was performed with the Opal
seven-colour IHC Kit (NEL801001KT; PerkinElmer) containing the fluorophores:
DAPI, Opal 520, Opal 540, Opal 570, Opal 620, Opal 650 and Opal 69056. Slides
were boiled in Tris-EDTA buffer for antigen retrieval and removal of Ab-TSA
complexes. Primary antibodies used are listed in Supplementary Table 3. A cocktail
of monoclonal antibodies (moAbs, also called Tumour marker) directed towards
two melanoma-associated antigens was added to each panel, including anti-
tyrosinase and anti-SOX10. After Ab staining, slides were counterstained with
DAPI for 5 min and enclosed in Fluoromount-G (0100-01; Southern Biotech).
Tissue imaging and quantitative digital analysis. Whole tissue slides were
imaged using Vectra Intelligent Slide Analysis System (Version 3.0.4, PerkinElmer
Inc.). This imaging technology combines imaging and spectroscopy to collect entire
spectra at every location of the image plane. Regions of interest (ROI) were selected
using Phenochart (Version 1.0.9, PerkinElmer Inc.). Images of single stained tissues
for each reagent were used to build spectral libraries of the single dyes by using the
inForm Advanced Image Analysis Software (Version 2.4.1, PerkinElmer Inc.).
These spectral libraries were used to unmix the original multispectral images
obtained with the Vectra imaging system (Supplementary Fig. 4c), to obtain an
accurate and specific quantification of the Cleaved-Caspase-3 negative, CD45
positive (Cl. Cas3−CD45+) signal. A selection of 10–20 representative original
multispectral images was used to train the inForm Advanced Image Analysis
Software (Version 2.4.1, PerkinElmer Inc.) for quantitative image analysis (tissue
segmentation, cell segmentation and phenotyping)56,57. All settings applied to the
training images were saved within an algorithm allowing batch analysis of multiple
original multispectral images of the same tissue. Phenochart (Version 1.0.9, Per-
kinElmer Inc.) was used to select the areas for analysis; this consisted of the entire
reconstructed tissue. Both background area and tissue area (region of interest or
ROI; Supplementary Fig. 4b) were defined by trainable tissue segmentation, based
on morphological features and expression of DAPI (for efficient cell segmentation)
and tumour markers (for discrimination of areas containing tumour cells). A
region of disinterest (ROD) was manually drawn in a qualitative manner over the
stratum corneum, dermal border and injection site in order to reduce the auto-
fluorescent signal caused by the structural characteristics of those regions. To
appreciate the cell distribution patterns at low resolution, we clustered the cell
positions using hierarchical mean linkage clustering, with a distance threshold of
150 mm (i.e., clusters whose centres were more than 150 mm apart were not
joined). Single-cell-based information was saved to a file format compatible with
flow and image cytometry data analysis software FlowJo (Version 10, Treestar).
Time-lapse image acquisition and analysis. All time-lapse experiments were
performed using multiparameter multiphoton microscopes (TriMScope-II, LaVi-
sion BioTec, Bielefeld, Germany), equipped with water objectives (Olympus
XLPLN25XWMP2 1.05 NA and Nikon MRD77220 25×1.1 NA), on a temperature-
controlled stage (recorded temperature in samples 35.4 °C). 4D time-lapse
recordings were acquired by sequential scanning with 950 nm (eGFP and PKH26)
and 1090 nm (SHG) excitation. Emission was bandpass filtered (525/50 eGFP and
SHG, 620/60 PKH26) and detected with GaAsP photomultiplier detectors
(Hamamatsu, H7422A-40). Areas of interest were imaged with 120 s time interval
between individual scans over a 2-h period, starting ~4 h after injection of pre-
labelled cDC2s. Consecutive images were acquired with a step-size of 5 μm. Images
were analysed using the open source-imaging platform, Fiji (imageJ 64 Bit for
Windows). Drifts in time-lapse recordings were corrected using the Descriptor-
based series registration (2d/3d+ t) plug-in ref. Gaussian filtering (0.5) was applied
to all images prior to analysis. If necessary, images were scaled and adjusted for
brightness and contrast to enhance visualization.
Step-by-step image processing and analysis of DC cell morphology is depicted
in Supplementary Fig. 5a–c. Five fields-of-view (FOVs) from two independent
experiments were analysed, over 50-min time-lapse two-photon microscopy
movies. In each FOV, the tumour area represented 10–20% of the total imaging
area. Maximum intensity projections of three consecutive z-stacks, for a total z-size
of 10 μm were generated. Regions of interest (ROIs) were drawn to define DCs in
proximity to tumour (distance <100 μm, Proximal) and DCs distant from tumour
(distance >100 μm, Distal). A semi-automated analysis of cell shape parameters
within either proximal or distant ROIs was performed. Cell clusters were excluded
from the analysis based on size. Roundness was used as a measurement of how cell
shape is close to a circle (whereby, 1= circular cell, 0= elongated cell), and to
indicate degree of cell protrusion. In our analysis, a roundness factor of ~0.6 was
calculated in cells with a typical hand-mirror-shape phenotype (Supplementary
Fig. 5b). DC morphology was assessed in time-lapse images with a time-lapse
interval of 10 min. Results from two experiments are shown in Supplementary
Fig. 5c. The image processing and quantification steps of DCs (magenta)
interacting with tumour cells (BLM-GFP, green) in OMCs, are depicted in
Supplementary Fig. 5d. Five fields-of-view (FOVs) from two independent
experiments were analysed, with a time-lapse interval of 2 min. In each FOV, the
area occupied by tumour cells represents 10–20% of the total imaging area
(Supplementary Fig. 5e). Maximum intensity projections of three consecutive
z-stacks, for a total z-size of 10 μm were generated. The semi-automated
quantification of DC-tumour interactions is based on the measurement of mean
gray values of GFP pixel intensities (tumour) that overlay with DC selections.
Resulting mean gray values were corrected by background subtraction. The
percentage of DCs interacting with tumour cells over total DCs was reported for
each area of interest.
Flow cytometry and fluorescent-activated cell sorting (FACS). A complete list
of antibodies used in the study is reported in Supplementary Table 1. Dead cells
were identified using Fixable Viability Dye eFluor® 506 or 450 (Affymetrix,
eBiosciences) and excluded from the analysis. For surface staining: cells were
incubated in 2% human serum for the blocking of non-specific antibody binding to
receptors (10 min, 4 °C) and subsequently stained with directly labelled primary
antibodies (30 min, 4 °C) (Supplementary Table 1). For IL-6 intracellular staining:
cells were stimulated with LPS (1 μg/mL, Sigma) for 6 h and GolgiPlug (BD
Biosciences) was added in the last 5 h of the assay. After staining of surface markers
(using directly labelled anti-CD45, anti-CD1c and anti-CD14 Abs), cells were
washed, fixed and permeabilized with Cytofix/Cytoperm buffer (BD Biosciences)
and stained with FITC-labelled anti-IL-6 (BioLegend). Acquisition was performed
on a FACSVerse flow cytometer (BD Biosciences) and FlowJo analysis software
(Treestar) was used for data analysis. Fluorescent-activated cell sorting (FACS) was
performed using the ARIA SORP (Becton Dickinson, Franklin Lakes, NJ). Anti-
CD45, anti-CD1c and anti-CD14 sterile antibodies were used. Briefly, 2 days post-
injection tumour-free OSCs and OMCs were digested, under sterile conditions, and
the cell suspensions filtered, stained and cells were sorted with >98% purity.
Mixed lymphocyte reaction and activated T-cell phenotype. The ability of
cDC2s (CD1c+CD14−) and CD14+ DCs (CD1c+CD14+), isolated from OSCs and
OMCs, to induce T-cell proliferation was tested in a mixed lymphocyte reaction
(MLR). A total of 3 × 104 CFSE-labelled unstimulated allogeneic CD3+ T cells from
a healthy donor were seeded in a round bottom 96-well/plate and 15,000 (1:2
ratio), 6000 (1:5 ratio) or 0/myeloid cells were added. The percentage of pro-
liferated T cells was analysed at day 5 after staining with anti-CD3 and anti-CD8
antibodies. For assessing the myeloid subsets stimulatory potential on autologous
T cells, 1 × 105 autologous unfractionated CD3+ T cells were cultured with 10,000
(1:10 ratio) or 0/myeloid cells. After 5 days, T cells were stained with anti-CD3,
CD8, CD25 and HLA-DR (see Supplementary Table 1) and acquired at the
FACSVerse (BD Biosciences).
Gene expression analysis. Total RNA was extracted from FAC-sorted immune
cells using Trizol (Invitrogen), and cDNA was generated using the SuperScript II
Reverse Transcriptase Kit (ThermoFisher Scientific). cDNA was then used as a
template for messenger RNA (mRNA) amplification using the TranscriptAid T7
High Yield Transcription Kit (Thermo Scientific). Amplified (aRNA) was purified
using Agencourt RNAClean XP beads (Beckman Coulter, Brea, CA) prior to
Nanodrop quantification. 500 ng/mL of aRNA were used for reverse transcription
with Superscript II (ThermoFisher Scientific). The resulting cDNA was used as a
template. qPCR using FastStart SYBR Green Master (Roche Diagnostic GmbH) was
performed on a CFX96 real-time cycler (Bio-Rad). The 2−ΔCt method, in which Ct
represents the threshold cycle, was applied. Samples were run in triplicate. Relative
gene expression was determined by normalizing the gene expression of each target
gene to β-actin (ACTB). Primer sequences are listed in Supplementary Table 4.
Quantification of soluble factors detection in supernatant. Forty-five soluble
factors in 48 h cultured supernatant from fibroblasts, BLM, OSC and OMC were
quantified by using either the Luminex-based bead multiplex immunoassays
(Millipore) or a dedicated ELISA for PGE2 (R&D Systems) according to the
respective manufacturers’ instructions. Heatmap showing concentrations of soluble
factors among conditions were generated with Rstudio (Version 1.2.1335, RStudio
Team 2018), using log2-transformed cytokine concentrations58.
T-cell analysis of PBMCs injected in the OMC. Peripheral blood mononuclear
cells (PBMCs) were isolated from buffy coats obtained from healthy volunteers
(Sanquin) and purified via centrifugation over a Ficoll. OMCs containing BLM cells
were generated as described above. Then, PBMCs were microinjected into the
dermis of the generated OMCs (0.5 × 106 cells/OMC) using a microneedle array
system (kindly provided by Nanopass Technology Ltd, Israel). Immunocompetent
OMCs were cultured for additional two days in X-VIVO-15 medium plus 10%
human serum. In parallel, an aliquot of PBMCs was also cultured in a standard
plate (2D) and maintained in the same culture medium. After 48 h the percentage
of CD3+ and CD8+ cells was evaluated by flow cytometry. Briefly, dead cells were
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identified using the Fixable Viability Dye eFluor® 506 (Affymetrix, eBiosciences)
and excluded from the analysis. Then, cells were incubated in 2% human serum for
the blocking of non-specific antibody binding to receptors (10 min, 4 °C) and
subsequently stained with directly labelled primary antibodies to CD45, CD3 and
CD8 (30 min, 4 °C) (Supplementary Table 1).
Generation and analysis of patient-derived OMCs. Patient-derived metastatic
melanoma samples were processed as described above. The resulting single-cell
suspensions were microinjected into a de-epidermized, decellularized human
dermis using the microneedle array system (Nanopass Technology Ltd, Israel). The
resulting patient-derived OMCs were cultured for two days in X-VIVO-15 medium
plus 10% human serum. Then, microtissues containing the patient material were
fixed and processed for paraffin embedding. Fluorescent Multiplex IHC staining on
tissue sections was performed using the following antibodies: CD3, CD8 and
tumour marker. The latter consists of a mix of antibodies recognizing the mela-
noma antigens, HMB45 (gp100), MelanA (MART-1), Tyrosinase and SOX10
(Supplementary Table 2). Prior to injection, flow cytometry was conducted on the
same patient-derived samples using antibodies recognizing CD3, CD8 and CD45
(Supplementary Table 1). Dead cells were identified using the Fixable Viability Dye
eFluor® 506 (Affymetrix, eBiosciences) and excluded from the analysis. For auto-
logous experiments within the OMC the patient tumour suspension-derived CD45-
negative fraction, containing tumour and stromal cells, was allowed to grow over
two days within the dermal scaffold and CD14+ monocytes were isolated from
peripheral blood and injected into the model similar to what described for cDC2s.
Similarly, after 2 days the OMC-educated phenotype of monocytes was inter-
rogated by flow cytometry on the digested OMC suspension.
Statistical analysis. Statistical analysis was performed using GraphPad Prism V6
and V8 (GraphPad Software Inc, San Diego, CA). Unless otherwise indicated,
results are presented as mean±SEM in scattered dot plots. The significance between
two groups was analysed by two-tailed paired or unpaired Student’s t tests or
Wilcoxon matched-pairs signed-rank test. Multiple comparisons were performed
using one-way or two-way analysis of variance (ANOVA) followed by multiple
comparisons tests, as indicated in each figure legend. Statistical significance was
annotated as follows: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All the data supporting the findings of this study are available within the article and its
supplementary information files and from the corresponding author upon reasonable
request. The source data underlying Figs. 2d, 4b–e, 5a–d, 6a, d–f, 7b, c, 8b, e and
Supplementary Figs. 1d, f, 5c, e, f, 7a, c, 8a, b, 9a–d are provided as a Source data file. A
reporting summary for this article is available as a Supplementary Information file.
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